5 news items
Karyopharm Presents Updated Exploratory Subgroup Analyses from SIENDO Study in Patients with Advanced or Recurrent TP53 Wild-Type Endometrial Cancer During 2024 ASCO Plenary Series: Rapid Abstract Updates
KPTI
1 Jun 24
of the study is progression free survival (PFS), as assessed by an investigator, with overall survival as a key secondary endpoint. Further, in connection
Karyopharm Reports First Quarter 2024 Financial Results and Highlights Recent Company Progress
KPTI
8 May 24
by Karyopharm's global partners. Selinexor is also being investigated in several other mid- and late-stage clinical trials across multiple high unmet
Karyopharm Announces Significant Refinancing Transactions and Amended Royalty Agreement Extending Vast Majority of Its Debt Maturities into 2028 and 2029
KPTI
8 May 24
by the U.S. Food and Drug Administration and other regulatory authorities, investigational review boards at clinical trial sites and publication review
Karyopharm Announces Presentations In Endometrial Cancer And Myelofibrosis At The 2024 American Society Of Clinical Oncology Annual Meeting
KPTI
24 Apr 24
areas by Karyopharm's global partners. Selinexor is also being investigated in several other mid- and late-stage clinical trials across multiple high
Karyopharm Announces Presentations in Endometrial Cancer and Myelofibrosis at the 2024 American Society of Clinical Oncology Annual Meeting
KPTI
24 Apr 24
is also being investigated in several other mid- and late-stage clinical trials across multiple high unmet need cancer indications, including
- Prev
- 1
- Next